Access to Single-Fraction Palliative Radiation Therapy in Cancer Patients Enrolled in Hospice

Cancer Metastatic Clinical Trial

— SFPRT  

Official title:

Impact of Access to Single-Fraction Palliative Radiation Therapy in Cancer Patients Enrolled in Hospice

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04049188
• Other study ID #: 00019460
• Secondary ID: 20181015
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2020
• Est. completion date: December 31, 2021

Study information

• Verified date: January 2020
• Source: Care Partners
• Contact: Andy Kyler, BSN, MBA
• Phone: 5036192621
• Email: andy.kyler[@]carepartners.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Feasibility study to report on the impact of ACCESS of single-fraction radiation therapy on cancer patients with bone metastases enrolled in hospice care.

Description:

Hospice care for terminally ill patients with metastatic cancer improves quality of life, pain control, and potentially also survival when patients are enrolled early.1-3 However, hospice programs are often seen by patients and their caregivers as the last resort after exhaustion of all effective treatment options. The need to revoke active treatment (for all hospice patients with cancer outside of the VA system) discourages hospice enrollment.

This study aims to understand and analyze barriers to access specifically for short course palliative radiation therapy in cancer patients enrolled in hospice.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 31
• Est. completion date: December 31, 2021
• Est. primary completion date: January 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Solid Tumor Malignancies and Multiple Myeloma with Bone Metastases and Associated Bone Pain Enrolled in Hospice

Exclusion Criteria:

• Decisionally-Impaired Subjects, Pregnant Women

Related Conditions & MeSH terms

• Cancer Metastatic

Intervention

Radiation:
• Single-Fraction Palliative Radiation Therapy
All subjects will be undergo single-fraction palliative radiation therapy who have cancer and associated bone metastases and symptomatic bone pain.

Locations

Country	Name	City	State
United States	CarePartners	Hillsboro	Oregon

Sponsors (3)

Lead Sponsor	Collaborator
Care Partners	OHSU Knight Cancer Institute, Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Opioid Use for Pain Management	Opioid Dosage (mg/day)	Through study completion, an average of 1 year
Secondary	Improved Quality of Life Measures	Questionnaires using Herth Hope Index, Timed Up and Go, and Edmonton Symptom Assessment Scale	During study completion
Secondary	Improved Activities of Daily Living	Questionnaires using Hearth Hope Index, Timed Up and Go, and Edmonton Symptom Assessment Scale	During study completion